17 May 2016 - Submitted data deemed to be unsuitable.

Vismodegib (Erivedge) has been available since 2013 for the treatment of patients with locally advanced basal cell carcinoma or symptomatic metastatic basal cell carcinoma and has already been subjected to an early benefit assessment. The G-BA limited its February 2014 decision to two years, which is why the manufacturer has resubmitted a dossier.

In its second benefit assessment, the IQWiG has come to the same conclusion as before; the data submitted do not show superiority over the appropriate comparator therapy. An additional benefit of vismodegib is therefore not shown.

For more details, go to: https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/vismodegib-bei-basalzellkarzinom-zusatznutzen-nicht-belegt.7337.html?&et_cid=4&et_lid=%25208